Quick Summary — CABR scores higher on quality with 5.3/10 vs CRON's 5.2/10. CABR trades at $1.25 while CRON trades at $2.73. Both analyzed daily using SEC EDGAR data across 13 institutional models.
CABR scores higher with a 5.3/10 quality rating vs CRON's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $1.25, CABR trades +69.0% above its Bayesian DCF fair value of $0.39, while CRON at $2.73 trades +5.9% below its estimate of $2.89. CABR shows a wider gap between price and intrinsic value.
CABR earns a Quality of Company score of 5.3/10 compared to CRON's 5.2/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both CABR and CRON to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both CABR and CRON operate in Drug Manufacturers - Specialty & Generic, which has 79 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare CABR vs CRON differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.